Results 21 to 30 of about 11,066 (220)

LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality [PDF]

, 2016
Lysergic acid diethylamide (LSD) is used recreationally and has been evaluated as an adjunct to psychotherapy to treat anxiety in patients with life-threatening illness.
CG Frye, CJ Harmer, CM Hysek, CM Hysek, CM Hysek, CS Grob, DE Nichols, Felix Müller, FX Vollenweider, G Bedi, I Dziobek, KA MacLean, KH Preller, KP Kuypers, M Kometer, Matthias E Liechti, MC Mithoefer, MC Mithoefer, MC Wardle, MC Wardle, MG Kirkpatrick, MG Kirkpatrick, MP Bogenschutz, MW Johnson, P Gasser, P Gasser, P Oehen, P. Strajhar, Patrick C Dolder, Patrick C. Dolder, PC Dolder, R Hurlemann, RL Carhart-Harris, RL Carhart-Harris, RO Murphy, RR Griffiths, RR Griffiths, Stefan Borgwardt, T Passie, W Janke, Y Schmid, Y Schmid, Yasmin Schmid   +42 more
core   +1 more source

Modern Clinical Research on LSD [PDF]

, 2017
All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients.
A Garcia-Romeu, A Rickli, A Rickli, AB Wolbach Jr, AL Halberstadt, AL Halberstadt, Andrea E. Steuer, AV Lebedev, CM Hysek, CM Hysek, CS Grob, D Holland, D Marona-Lewicka, D Nutt, DB Terhune, DE Nichols, DE Nichols, DE Nichols, DV Sheehan, E Gouzoulis-Mayfrank, E Studerus, E Tagliazucchi, EA Schindler, F Hasler, F Mueller, FL Osorio, FX Vollenweider, FX Vollenweider, J Riba, J Seibert, J Speth, JC Bouso, JH Halpern, JJ Rucker, KA MacLean, KH Preller, KH Preller, KH Preller, KPC Kuypers, L Roseman, L Roseman, LD Simmler, LE Hollister, M Johnson, M Kaelen, M Kaelen, M Kometer, M Kometer, MA Geyer, Matthias E Liechti, ME Liechti, MJ Baggott, MP Bogenschutz, MW Johnson, P Gasser, P Gasser, P Strajhar, Patrick C. Dolder, PC Dolder, PC Dolder, PC Dolder, PS Hendricks, R Kraehenmann, Rainer Kraehenmann, RE Belleville, RG Dos Santos, RJ Strassman, RJ Strassman, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RR Griffiths, RR Griffiths, S Ross, SD Muthukumaraswamy, T Passie, TS Krebs, TS Krebs, WE Fantegrossi, WN Pahnke, WN Pahnke, Y Schmid   +85 more
core   +1 more source

Classical and non-classical psychedelic drugs induce common network changes in human cortex

NeuroImage, 2023
The neurobiology of the psychedelic experience is not fully understood. Identifying common brain network changes induced by both classical (i.e., acting at the 5-HT2 receptor) and non-classical psychedelics would provide mechanistic insight into state ...
Rui Dai, Tony E. Larkin, Zirui Huang, Vijay Tarnal, Paul Picton, Phillip E. Vlisides, Ellen Janke, Amy McKinney, Anthony G. Hudetz, Richard E. Harris, George A. Mashour   +10 more
doaj   +1 more source

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Frontiers in Psychiatry, 2020
BackgroundObservational data and preliminary studies suggest serotonin 2A agonist psychedelics may hold potential in treating a variety of substance use disorders (SUDs), including opioid use disorder (OUD).AimsThe study aim was to describe and analyze ...
Albert Garcia-Romeu, Alan K. Davis, Alan K. Davis, Earth Erowid, Fire Erowid, Roland R. Griffiths, Roland R. Griffiths, Matthew W. Johnson   +7 more
doaj   +1 more source

Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects [PDF]

, 2017
Lysergic acid diethylamide (LSD) induces profound changes in various mental domains, including perception, self-awareness and emotions. We used functional magnetic resonance imaging (fMRI) to investigate the acute effects of LSD on the neural substrate ...
Borgwardt, S., Dolder, P. C., Harder, S., Lang, U. E., Lenz, C., Liechti, M. E., Mueller, F., Schmid, Y.   +7 more
core   +1 more source

Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities [PDF]

, 2015
Classical psychedelics are psychoactive substances, which, besides their psychopharmacological activity, have also been shown to exert significant modulatory effects on immune responses by altering signaling pathways involved in inflammation, cellular ...
Attila Szabo
core   +5 more sources

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens [PDF]

, 2016
The present study investigated interactions between the novel psychoactive tryptamines DiPT, 4-OH-DiPT, 4-OH-MET, 5-MeO-AMT, and 5-MeO-MiPT at monoamine receptors and transporters compared with the classic hallucinogens lysergic acid diethylamide (LSD ...
Hoener, Marius C., Liechti, Matthias E., Moning, Olivier D., Rickli, Anna   +3 more
core   +1 more source

Over 30 million psychedelic users in the United States [v1; ref status: indexed, http://f1000r.es/w8]

F1000Research, 2013
We estimated lifetime prevalence of psychedelic use (lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), mescaline, and peyote) by age category using data from a 2010 US population survey of 57,873 individuals aged 12 years and older.
Teri S Krebs, Pål-Ørjan Johansen
doaj   +1 more source

Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD

eLife, 2021
Psychoactive drugs can transiently perturb brain physiology while preserving brain structure. The role of physiological state in shaping neural function can therefore be investigated through neuroimaging of pharmacologically induced effects.
Joshua B Burt, Katrin H Preller, Murat Demirtas, Jie Lisa Ji, John H Krystal, Franz X Vollenweider, Alan Anticevic, John D Murray   +7 more
doaj   +1 more source

Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide [PDF]

, 2016
This paper reports on the effects of LSD on mental time travel during spontaneous mentation. Twenty healthy volunteers participated in a placebo-controlled crossover study, incorporating intravenous administration of LSD (75 μg) and placebo (saline ...
Cohen S, Grof S, James W, Reinhart T, Schacter DL, Schneider K, Speth J, Stickgold R, Suddendorf T, Suddendorf T, Tolle E, Tulving E, Washington SD, Xiao Y, Zahavi D   +14 more
core   +2 more sources